Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (MYG 151211)
- Institute for Clinical Evaluative Sciences
- Ontario Ministry of Health and Long-Term Care
This publication has 28 references indexed in Scilit:
- Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in SpainAdvances in Therapy, 2024
- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialNature Medicine, 2022
- CLINICAL PRACTICE PATTERNS AND ATTITUDES ABOUT PRESCRIBING SGLT2 INHIBITORS AT A SINGLE-CENTER ACADEMIC SAFETY-NET HOSPITALJACC, 2021
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 UpdateCanadian Journal of Diabetes, 2020
- Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic ReviewValue in Health, 2018
- Pharmacologic Glycemic Management of Type 2 Diabetes in AdultsCanadian Journal of Diabetes, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015